Showing 3941-3950 of 9336 results for "".
- Lower Neighborhood SES Linked to Increased HS Severity at Diagnosis: Analysishttps://practicaldermatology.com/news/lower-neighborhood-ses-linked-to-increased-hidradenitis-suppurativa-severity-at-diagnosis/2483997/New research suggests that lower neighborhood socioeconomic status (nSES) was associated with more severe hidradenitis suppurativa (HS) at the time of diagnosis. The recent cross-sectional analysis of 462 patients newly diagno
- Analysis: Long-Term Ixekizumab Not Linked to Higher Cancer Risk in PsO, PsAhttps://practicaldermatology.com/news/analysis-long-term-ixekizumab-not-linked-to-higher-cancer-risk-in-pso-psa/2483983/A recent pooled analysis of 25 randomized clinical trials (RCTs) found no increased risk of malignant neoplasms with long-term ixekizumab (IXE) therapy in patients with psoriasis (PsO), psoriatic arthritis (PsA), or axial spondyloarthritis (axSpA).
- Study: Epidermal Mitochondrial Loss Linked to Skin Aging and Fat Gainhttps://practicaldermatology.com/news/study-epidermal-mitochondrial-loss-linked-to-skin-aging-and-fat-gain/2483941/A new study published in the Journal of Investigative Dermatology suggests mitochondrial decline in epidermal keratinocytes plays a central role in skin aging and may also contribute to age-related obesity.
- Global CME Conference to Spotlight Eczema Burden, Treatment Advanceshttps://practicaldermatology.com/news/global-cme-conference-to-spotlight-eczema-burden-treatment-advances/2483912/Health & Wellness Global Alliance will host its inaugural H&W Global Dermatology CME Conference November 12-16, 2025, aiming to spotlight the international burden of eczematous diseases. The event aligns with the mission
- Dr. Andrew Alexis Highlights 2-MNG as Option to Treat Acne-Related PIHhttps://practicaldermatology.com/news/dr-andrew-alexis-highlights-2-mng-as-option-to-treat-acne-related-pih/2483902/The topical agent 2-Mercaptonicotinoyl glycine (2-MNG), also marketed as Melasyl, could be key to treating acne-related postinflammatory hyperpigmentation (PIH) in skin of color, Andrew Alexis, MD, MPH, said at the Skin of Color Update in New York, New York. Dr. Alexis presented on managin
- FDA Approves Libtayo for Adjuvant Treatment of High-Risk CSCChttps://practicaldermatology.com/news/fda-approves-libtayo-for-adjuvant-treatment-of-high-risk-cscc/2483899/The FDA has approved cemiplimab-rwlc (Libtayo, Regeneron) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence following surgery and radiation, according to a statement from the agency.
- Pfizer and GWU Renew Grant Program to Expand Teledermatology Access for Inflammatory Skin Conditionshttps://practicaldermatology.com/news/pfizer-and-gwu-renew-grant-program-to-expand-teledermatology-access-for-inflammatory-skin-conditions/2483889/Pfizer Global Medical Grants and The George Washington University (GWU) have renewed their joint grant program focused on broadening access to dermatologic care in underserved U.S. communities. According to a GWU press announc
- Analysis: Ceramide Skincare from Birth May Mitigate Pediatric ADhttps://practicaldermatology.com/news/analysis-ceramide-skincare-from-birth-may-mitigate-pediatric-ad/2483872/A new consensus paper offers clinical recommendations to address the complex interplay of skin barrier dysfunction and SAIGE (Staphylococcus aureus colonization, immunologic, genetic, and environmental) factors in pediatric atopic dermatitis (AD).
- Dr. Jennifer Soung: Ask Patient’s Permission Before Talking GLP-1shttps://practicaldermatology.com/news/dr-jennifer-soung-ask-patients-permission-before-talking-glp-1s/2483863/GLP-1 treatments have become commonplace in dermatology practices, with both aesthetic and medical dermatology implications heavily involved. Talking to patients about the latter issue, however, can prove challenging. Despite the mounting literature indicating that GLP-1 agonists can help allevia
- Roflumilast 0.05% Gains FDA Approval for Children 2-5 with ADhttps://practicaldermatology.com/news/roflumilast-005-gains-fda-approval-for-children-2-5-with-ad/2483862/The US Food and Drug Administration (FDA) has approved roflumilast cream 0.05% (Zoryve®, Arcutis Biotherapeutics) for the treatment of mild-to-moderate atopic dermatitis (AD) in children 2 to 5 years old. This once-daily topical phosphodiesterase-4 (PDE4) inhibitor